Previous 10 | Next 10 |
2023-08-13 05:24:05 ET Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Conference Call August 10, 2023, 04:30 PM ET Company Participants Mark Flather - VP of IR Shawn Singh - CEO Josh Prince - SVP of Business Operations Conference Call Participants ...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results for the first qua...
2023-08-11 08:16:36 ET Cano Health ( CANO ) -48% after Q2 earning release . Yield10 Bioscience ( YTEN ) -46% . Maxeon Solar Technologies, Ltd. ( MAXN ) -26% after Q2 earning release . LQR House ( LQR ) -17% . Vistagen Therapeutics ( ...
2023-08-10 17:22:39 ET VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q1 GAAP EPS of -$0.94 misses by $0.08 . Revenue of $0.17M (-45.2% Y/Y). For further details see: VistaGen Therapeutics GAAP EPS of -$0.94 misses by $0.08, revenue of $0.17M
Positive top-line results from Phase 3 PALISADE-2 trial of rapid-onset fasedienol (PH94B) nasal spray in social anxiety disorder (SAD) Itruvone (PH10) nasal spray now staged for Phase 2B clinical development as a stand-alone, non-systemic treatment for major depressive disorder (MDD) ...
2023-08-10 08:27:32 ET Capri Holdings ( CPRI ) +57% confirms $8.5B deal to acquire Capri Holdings. Edible Garden AG ( EDBL ) +43% Q2 earnings call release Missfresh Limited ( MF ) +27% . AppLovin Corporation ( APP ) +26% surges as BofA says 'multi...
Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to report its Q1 2024 financial ...
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, August 1...
2023-08-08 12:46:20 ET Gainers: Infinity Pharmaceuticals ( INFI ) +56% . Bright Minds Biosciences ( DRUG ) +46% . Tilray Brands ( TLRY ) +31% . Paymentus Holdings (PAY) +33% . Gorilla Technology Group ( GRRR ) +28% . Cardiff Onco...
2023-08-08 10:21:19 ET Gainers: Bright Minds Biosciences ( DRUG ) +62% . Bionomics ( BNOX ) +24% . Novo Nordisk ( NVO ) +18% . Quanterix ( QTRX ) +17% . Tilray Brands ( TLRY ) +18% . Losers: Vistagen Therapeutics ( VTGN ...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...